natgillin/translations-raw huggingface dataset:
Dysphagia may persist for two to three weeks after injection, but has been reported in one case to last five months. 
Disfagija lahko traja dva do tri tedne po injiciranju, v enem primeru pa so poročali o petmesečni disfagiji.
Uncommon: speech disorders (dysphonia), weakness (asthenia), muscle pain (myalgia), headache, shaking (tremor), eye pain, diarrhoea, dry mouth, vomiting, inflammation of the colon (colitis), skin rash, skin redness (erythema), itching (pruritus), sweating increased, skeletal pain, injection site inflammation, injection site tenderness 
motnje govora (disfonija), šibkost (astenija), bolečine v mišicah (nialgija), glavobol, tresenje (tremor), bolečina v očesu, driska, suha usta, bruhanje, vnetje debelega črevesa (kolitis), kožni izpuščaj, rdečica kože (eritem), srbenje (pruritus), povečano potenje, bolečine v kosteh, vnetje na mestu injiciranja, občutljivost na mestu injiciranja
Barnes MP, Best D, Kidd L, Roberts B, Stark S, Weeks P, et al. 
3 Barnes MP, Best D, Kidd L, Roberts B, Stark S, Weeks P, et al. The use of Botulinum toxin type-B in the treatment of patients who have become unresponsive to Botulinum toxin type-A -- initial experiences.
Usually, the first onset of effect is observed within four days after injection. 
Prvi učinek je po navadi viden štiri dni po injiciranju.
Swallowing difficulties can last for up to two to three weeks after injection, for one patient a duration of up to five months is known. 
Težave pri požiranju lahko trajajo dva do tri tedne po injiciranju, pri enem bolniku pa so poročali tudi o pet mesecev trajajočih težavah.
The median first onset of effect is observed within seven days after injection. 
Mediana opažanja pojava prvega učinka je sedem dni po injiciranju.
Usually, the first onset of effect is observed within seven days after injection. 
Prvi učinek je po navadi viden sedem dni po injiciranju.
Tell your doctor immediately or go to the casualty department at your nearest hospital if you suffer from any of these symptoms. 
Če imate katerega koli od navedenih simptomov, takoj obvestite zdravnika ali pojdite na oddelek za nujno zdravniško pomoč pri najbližji bolnišnici.
A similar dose-efficacy response relationship has been demonstrated for Xeomin and Botox after one injection in spasmodic torticollis Phase III study. 
V študiji III. faze za spastični tortikolis je bila dokazana podobna povezava med odmerkom in učinkom za zdravili Xeomin in Botox po eni injekciji.
Both Phase I studies showed equal doses of Xeomin to be as effective as Botox in the EMG measurements; it was clearly demonstrated that the paralytic effects of Xeomin and Botox increased with ascending doses and a comparable trend was seen in a Phase II study. 
Obe študiji I. faze sta pokazali, da so pri meritvi z EMG odmerki zdravila Xeomin enako učinkoviti kot enaki odmerki zdravila Botox.
The median first onset of effect is observed within four days after injection. 
Mediana opažanja pojava prvega učinka je štiri dni po injiciranju.
• The active substance is Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins 
• zdravilna učinkovina je nevrotoksin bakterije Clostridium Botulinum tipa A (150 kD), brez beljakovin, ki tvorijo komplekse
Powder for solution for injection 
prašek za raztopino za injiciranje za intramuskularno uporabo
Uncommon: facial paralysis, facial muscle weakness, inflammation of the cornea (keratitis), everted margin of the lid (ectropion), double vision (diplopia), inverted margin of the lid (entropion), visual disturbance, blurred vision, dizziness, inflammatory skin reaction (dermatitis), tiredness 
ohromelost obraza, šibkost obraznih mišic, vnetje roženice (keratitis), obrnjenost roba veke navzven (aktropij), dvojni vid (diplopija), obrnjenost roba veke navznoter (entropij), motnje vida, zamegljen vid, omotica, vnetna reakcija na koži (dermatitis), utrujenost
Ecchymosis easily occurs in the soft tissues of the eyelid. 
V mehkih tkivih očesne veke lahko pride do ekhimoze.
PHARMACEUTICAL FORM AND CONTENTS Powder for solution for injection 1 vial 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek za pripravo raztopine za injiciranje.
U U U U 
Xeomin skupaj
Uncommon: muscle weakness, pins and needles (paraesthesia), headache, inflammation of the conjunctiva (conjunctivitis), dry mouth, skin rash, inflicted injury 
mišična šibkost, mravljinčenje (parestezija), glavobol, vnetje veznice (konjunktivitis), suha usta, kožni izpuščaj, poškodbe
WHAT XEOMIN IS AND WHAT IT IS USED FOR Xeomin is a medicine that relaxes the muscles. 
Xeomin je zdravilo, ki sprošča mišice.
Erythema multiforme, urticaria, psoriasis-like rash, pruritus, and allergic reactions have been described with the use of conventional preparations containing the Botulinum toxin type A complex, but their causal relationship remains unclear. 
Pri uporabi običajnih zdravil s kompleksom botulinskega toksina tipa A so poročali o multiformnem eritemu, urtikariji, izpuščaju, podobnem psoriazi, pruritusu in alergijskih reakcijah, vendar je vzročnoposledična povezava neznana.
HOW TO STORE XEOMIN 
SHRANJEVANJE ZDRAVILA XEOMIN
PHARMACEUTICAL FORM AND CONTENTS Powder for solution for injection 6 vials 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek za raztopine za injiciranje.
Twisted neck (spasmodic torticollis) 
Ukrivljen vrat (spastični tortikolis)
Reconstituted solution: Store in a refrigerator (2 - 8°C) Your doctor will reconstitute the medicine with physiological saline before use. 
Rekonstituirana raztopina: Shranjujte v hladilniku (2 °C-8 °C).
NAME OF THE MEDICINAL PRODUCT Xeomin 100 LD50 units powder for solution for injection [See Annex I - To be completed nationally] 
IME ZDRAVILA Xeomin 100 enot LD50 prašek za raztopino za injiciranje
Various forms of skin eruptions (erythema multiforme, urticaria, psoriasis-like rash), itching, and allergic reactions have been described with the use of conventional preparations containing the Botulinum toxin type A complex, but their causal relationship remains unclear. 
Pri uporabi običajnih zdravil s kompleksom botulinskega toksina tipa A so poročali o različnih oblikah kožnih izbruhov (multiformnem eritemu), srbenju, izpuščaju, podobnem psoriazi, pruritusu in alergijskih reakcijah, vendar je vzročno-posledična povezava neznana.
One case with severe dysphagia was reported in the Botox group. 
V skupini z zdravilom Botox so poročali o enem primeru resne disfagije.
Blepharospasm The following adverse reactions were reported with Xeomin: 
Blefarospazem Pri zdravljenju z zdravilom Xeomin so poročali o naslednjih neželenih učinkih:
Xeomin is injected into the medial and lateral orbicularis oculi of the upper lid and the lateral orbicularis oculi of the lower lid. Additional sites in the brow area, the lateral orbicularis and in the upper facial area may also be injected if spasms here interfere with vision. 
Zdravilo Xeomin se injicira v medialno in lateralno očesno orbikularno mišico zgornje veke ter lateralno očesno orbikularno mišico spodnje veke.
superficial punctate keratitis, lagophthalmos, eye irritation, photophobia, lacrimation Uncommon: keratitis, ectropion, diplopia, entropion, visual disturbance, blurred vision Rare: 
keratitis, ektropij, diplopija, entropij, motnje vida, zamegljen vid Redki: otekanje očesnih vek
PHARMACEUTICAL FORM Powder for solution for injection White powder 
FARMACEVTSKA OBLIKA Prašek za raztopino za injiciranje.
The powder is white. 
Bel prašek
Content (concentration) 
Farmacevtska oblika Pot uporabe zdravila vsebina (koncentracija)
Eyelid spasm (blepharospasm) The following side effects were reported with Xeomin: 
Krči vek (blefarospazem) Pri zdravljenju z zdravilom Xeomin so poročali o naslednjih neželenih učinkih:
Botulinum neurotoxin type A blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine. 
Farmakoterapevtska skupina: Mišični relaksanti s perifernim delovanjem, Oznaka ATC: M03AX01 Botulinski nevrotoksin tipa A blokira holinergični prenos na nevromuskularnih ploščicah, tako da zavira sproščanje acetilholina.
• the posology of Xeomin 
• odmerjanje zdravila Xeomin,
No more than 50 U should be given at any one injection site. 
Uporabijo se lahko odmerki do 300 e.. Na enem mestu injiciranja se ne sme dati odmerek, večji od 50 e..
1.25 U 
Faza 1b
rhinitis, upper respiratory tract infection Uncommon: dyspnoea, voice alteration 
rinitis, okužbe zgornjih dihal
Gastrointestinal disorders Common: 
disfonija Bolezni prebavil Pogosti:
Diplopia may develop as a result of Botulinum neurotoxin type A diffusion into the inferior oblique. 
Kot posledica difuzije botulinskega nevrotoksina tipa A v inferiorno poševno zrklno mišico se lahko razvije diplopija.
• in patients suffering from amyotrophic lateral sclerosis or other diseases which result in peripheral neuromuscular dysfunction 
Zdravilo Xeomin je treba uporabljati previdno: če se pojavijo kakršne koli motnje strjevanja krvi če bolniki prejemajo antikoagulante pri bolnikih z amiotrofično lateralno sklerozo ali drugimi boleznimi, ki povzročajo periferno nevromuskulatorno disfunkcijo pri izrazito šibkih ali atrofičnih ciljnih mišicah
Your body may develop antibodies after you received Botulinum toxin type A preparations. 
Po zdravljenju s pripravki botulinskega toksina tipa A lahko pride do nastanka protiteles v vašem telesu.
1 vial contains 100 LD50 units Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins. 
1 viala vsebuje 100 enot LD50 nevrotoksina bakterije Clostridium Botulinum tipa A (150 kD), brez beljakovin, ki tvorijo komplekse.
• eyelid spasm (blepharospasm) 
• krči vek (blefarospazem),
Spasmodic torticollis The following adverse reactions were reported with Xeomin: 
Spastični tortikolis Pri zdravljenju z zdravilom Xeomin so poročali o naslednjih neželenih učinkih:
• twisted neck (spasmodic torticollis) 
TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale (lestvica za oceno spazmičnega tortikolisa Toronto Western)
Nervous system disorders Uncommon: dizziness, facial paralysis 
omotica, obrazna paraliza
Eyelid spasm (blepharospasm) 
Krči vek (blefarospazem)
Xeomin100 LD50 units powder for solution for injection Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins 
Xeomin 100 enot LD50, prašek za raztopino za injiciranje nevrotoksin bakterije Clostridium Botulinum tipa A (150 kD), brez beljakovin, ki tvorijo komplekse
Dysphagia appears to be dose-dependent. 
Videti je, da je odvisna od odmerka.
QUALITATIVE AND QUANTITATIVE COMPOSITION 1 vial contains 100 LD50 units* of Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 viala vsebuje 100 enot LD50 nevrotoksina bakterije Clostridium Botulinum tipa A (150 kD), brez beljakovin, ki tvorijo komplekse.
dysphagia Uncommon: diarrhoea, dry mouth, vomiting, colitis 
diareja, suha usta, bruhanje, kolitis Bolezni kože in podkožja Občasni:
Intubation and assisted ventilation will become necessary until improvement if paralysis of the respiratory muscles occurs. 
Če pride do paralize dihalnih mišic, sta nujni intubacija in umetna ventilacija.
BEFORE YOU USE XEOMIN 
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO XEOMIN
Nervous system disorders Uncommon: headache, tremor 
glavobol, tremor
General disorders and administration site conditions Uncommon: asthenia, injection site inflammation, injection site tenderness 
astenija, vnetje na mestu injiciranja, občutljivost na mestu injiciranja
Medical supervision for up to several days and assisted ventilation may be necessary. 
Morda bosta nujna nekajdnevni zdravniški nadzor in umetno dihanje.
Xeomin100 LD50 units powder for solution for injection Clostridium Botulinum neurotoxin type A (150kD), free of complexing proteins For intramuscular use. 
Xeomin 100 enot LD50 prašek za raztopino za injiciranje nevrotoksin bakterije Clostridium Botulinum tipa A (150 kD), brez beljakovin, ki tvorijo komplekse
PACKAGE LEAFLET 
vzporedno preizkušanje
b) Distribution of the active substance in patients: 
Splošne značilnosti zdravilne učinkovine:
This does not affect the safety or effectiveness of the medicine. 
To ne vpliva na zdravje in učinkovitost zdravila.
The European Commission granted a marketing authorisation valid throughout the European Union for Stronghold on 25 November 1999. 
Evropska komisija je dovoljenje za promet z zdravilom Stronghold, veljavno po vsej Evropski uniji, izdala 25. novembra 1999.
Shampooing or soaking the animal two hours or more after treatment did not affect the medicine's effectiveness. 
Šamponiranje ali močenje dlake živali dve uri ali več po zdravljenju ni vplivalo na učinkovitost zdravila.
Other information about Stronghold: 
Druge informacije o zdravilu Stronghold:
It must also not be used in cats that are suffering from another disease or that are weakened and underweight for their size and age. 
Prav tako se ne sme uporabljati pri mačkah, ki imajo katero koli drugo bolezen ali so oslabljene oziroma podhranjene glede na svojo velikost in starost.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom to treat biting lice in cats and dogs, 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom zatiranje garij vrste Sarcoptes pri psih.
People with sensitive skin or known allergy to products of this type should handle Stronghold with caution. 
Osebe z občutljivo kožo ali znano alergijo na tovrstna zdravila naj z zdravilom Stronghold ravnajo previdno.
On the day of treatment, children must not handle treated animals and the animals should not sleep with their owners, especially children. 
Preprečiti je treba, da bi otroci na dan, ko je bilo zdravilo nanešeno, prišli v stik z živaljo, prav tako pa zdravljene živali ne smejo spati skupaj z lastniki, še zlasti ne z otroki.
It is available as a spot-on solution in 2 different concentrations (6% and 12%) and in tubes of various strengths (15, 30, 45, 60, 120, 240 and 360 mg).The concentration and the strength to use depends on the weight and species of the animal being treated. 
Na voljo je v obliki raztopine za kožni nanos v dveh različnih koncentracijah (6 % in 12 %) ter v tubah različnih jakosti (15, 30, 45, 60, 120, 240 in 360 mg).
Stronghold must not be used in animals under six weeks of age. 
Zdravilo Stronghold se ne sme uporabljati pri živalih do šestega tedna starosti.
Selamectin activates special proteins called ‘chloride channels' on the surface of nerve and muscle cells of the parasite, allowing charged chloride particles to enter nerve cells and disrupting their normal electrical activity. 
Selamektin aktivira posebne beljakovine, imenovane kloridni kanalčki na površini živčnih in mišičnih celic zajedavcev, kar kloridnim delcem omogoča, da vstopijo v živčne celice in ohromijo njihovo običajno električno dejavnost.
What is the risk associated with Stronghold? 
Kakšna tveganja so povezana z zdravilom Stronghold?
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Stronghold exceed the risks for the approved indications and recommended that Stronghold be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Stronghold večje od z njim povezanih tveganj, kadar se uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
If Stronghold comes into contact with the eyes, they should be flushed immediately with water and medical attention sought. 
Če pride zdravilo Stronghold v stik z očmi, jih je treba nemudoma sprati z obilo vode in poiskati medicinsko pomoč.
What benefit has Stronghold shown during the studies? 
Kakšne koristi je zdravilo Stronghold izkazalo med študijami?
Stronghold treatment was found to be effective after a single administration or repeated treatments at monthly intervals, depending on the type of infestation it was being used to treat or prevent. 
Zdravljenje z zdravilom Stronghold se je izkazalo za učinkovito po enkratnem odmerku ali ponavljajočih se zdravljenjih v mesečnih intervalih, odvisno od vrste infestacije, ki se zdravi ali preprečuje.
The effectiveness was then confirmed in field studies in cats and dogs by looking at the number of live parasites at various times after treatment. 
Nato so jo potrdili s terenskimi študijami pri mačkah in psih, v katerih so beležili število živih zajedavcev v različnih časovnih obdobjih po zdravljenju.
Stronghold 
Stronghold selamektin
Stronghold contains selamectin, which is an antiparasitic medicine that belongs to the ‘avermectin' class. 
Zdravilo Stronghold vsebuje selamektin, tj. antiparazitsko zdravilo iz razreda avermektinov.
In the treatment of sarcoptic mange in dogs, two treatments given 30 days apart were required to completely eliminate the mites in dogs. 
Pri zatiranju garij vrste Sarcoptes pri psih sta bili za popolno odstranitev garij potrebni dve zdravljenji v razmiku 30 dni.
In field studies, it reduced the flea comb counts by up to 98% in cats and 99% in dogs 90 days after treatment, as well as preventing flea eggs from hatching, and killing and preventing the development of flea larvae. 
V terenskih študijah je zdravilo 90 dni po zdravljenju zmanjšalo število izčesanih bolh za do 98 % pri mačkah in 99 % pri psih, prav tako pa je preprečilo izleganje jajčec bolh ter uničilo ličinke bolh in preprečilo njihov razvoj.
Why has Stronghold been approved? 
Zakaj je bilo zdravilo Stronghold odobreno?
The effectiveness of Stronghold against the specified parasites was investigated in laboratory studies in cats and dogs. 
Učinkovitost zdravila proti navedenim zajedavcem je bila proučena z laboratorijskimi študijami pri mačkah in psih.
Stronghold causes temporary alopecia (hair loss) at the application site in less than 1 in 1,000 cats. 
Zdravilo Stronghold povzroča začasno izpadanje dlake na mestu nanosa pri manj kot 1 od 1 000 mačk.
How has Stronghold been studied? 
Kako je bilo zdravilo Stronghold raziskano?
Used applicators should be disposed of immediately and not left within sight or reach of children. 
Uporabljene kapalke za nanos zdravila je treba nemudoma zavreči in morajo vselej biti izven pogleda in dosega otrok.
Field studies also showed that Stronghold was 100% effective in preventing heartworm disease in dogs and cats. 
Terenske študije so pokazale tudi, da je bilo zdravilo Stronghold 100-odstotno učinkovito pri preprečevanju obolenj zaradi infestacij s srčnimi glistami pri psih in mačkah.
The strength used and the number of administrations depend on the weight and species of the animal being treated, and the type of parasite. 
Uporabljena jakost in število odmerkov sta odvisna od mase zdravljene živali, živalske vrste, ki ji žival pripada, ter od vrste zajedavca.
Stronghold is an antiparasitic medicine that contains the active substance selamectin. 
Stronghold je zdravilo proti zajedavcem, ki vsebuje zdravilno učinkovino selamektin.
Treated animals must not be touched until the application area is dry. 
Izogibati se je treba dotikanja živali, na katere je bilo nanešeno zdravilo, dokler se mesto nanosa ne posuši.
Stronghold is highly flammable and should be kept away from heat, sparks, any open flame or other sources of ignition. 
Zdravilo je treba hraniti v varni razdalji od virov vročine, isker, odprtega ognja ali drugih virov vžiga.
Stronghold may produce clumping of the hair at the application site or the appearance of a small quantity of a white powder in less than 1 in 1,000 cats. 
Pri manj kot 1 od 1 000 mačk lahko povzroči zlepljanje dlake na mestu nanosa ali pojav manjših količin belega prahu.
What is Stronghold used for? 
Za kaj se zdravilo Stronghold uporablja?
The user must not smoke, eat or drink while handling Stronghold. 
Med uporabo zdravila Stronghold ni dovoljeno kaditi, jesti ali piti.
Stronghold was also effective in the treatment of adult intestinal hookworms in cats, adult intestinal roundworms in cats and dogs, and biting lice in dogs and cats. 
Zdravilo Stronghold je bilo učinkovito tudi pri zdravljenju odraslih črevesnih trakulj pri mačkah, odraslih črevesnih glist pri mačkah in psih ter infestacij s krvosesimi ušmi pri psih in mačkah.
Stronghold is used to treat and prevent infestations with parasites that live on the skin or in the fur of cats and dogs, such as fleas and mites, as well as treating worm parasites that live inside the body. 
Zdravilo Stronghold se uporablja za zdravljenje in preprečevanje infestacij z zajedavci, ki živijo na koži ali v dlaki mačk in psov, npr. z bolhami in garjami, ter za zatiranje črvastih zajedavcev, ki živijo v telesu.
It is also effective in treating ear mites in cats and dogs. 
Učinkovito je bilo tudi pri zatiranju ušesnih garij pri mačkah in psih.
The contents of the tube are squeezed onto the skin after parting the fur between the shoulder blades. 
Živali razmaknemo dlako med lopaticama, da se prikaže koža, in na to mesto stisnemo vsebino tube.
How does Stronghold work? 
Kako zdravilo Stronghold deluje?
What is Stronghold? 
Kaj je zdravilo Stronghold?
It can also be used as part of a treatment for flea allergy dermatitis (skin inflammation), to prevent heartworm disease in cats and dogs, to treat ear mites in cats and dogs, to treat adult intestinal roundworms and intestinal hookworms in cats, to treat adult intestinal roundworms in dogs, 
preprečevanje obolenj pri mačkah in psih, ki jih povzroča srčna glista; zatiranje ušesnih garij pri mačkah in psih; zatiranje odraslih črevesnih glist in črevesnih trakulj pri mačkah; zatiranje odraslih črevesnih glist pri psih; zatiranje krvosesih uši pri mačkah in psih;
There is no alternative available for this purpose in the EU at present. 
Za ta namen v EU trenutno ni na voljo nobena alternativa.
Member State EU/EEA 
Država članica EU/EEP
Quality, target animal safety, user safety and residues were not assessed in this referral procedure. 
Kakovost, varnost tarčnih živalskih vrst, varnost uporabnikov in ostanki se v tem napotitvenem postopku niso ocenjevali.
Thus, the PECsoil, and hence PECsurfacewater, could be conservatively reduced by 85% and not only by 69%. 
Tako bi lahko vrednost PECtla in z njo vrednost PECpovršinska voda konservativno znižali za 85 % in ne le za 69 %.
This value is used for the calculation of the initial PECsurfacewater value. 
Ta vrednost se uporablja pri izračunu začetne vrednosti
Therefore on 21 March 2013 Germany initiated a procedure under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing altrenogest to be administered orally to pigs and horses. 
Zato je Nemčija 21. marca 2013 sprožila postopek v skladu s členom 35 Direktive 2001/82/ES za zdravila za uporabo v veterinarski medicini, ki vsebujejo altrenogest za peroralno dajanje prašičem in konjem.
Consequently, the benefit-risk balance is considered positive. 
Zato je razmerje med tveganji in koristmi pozitivno.
The CVMP noted that measures are already in place to reduce runoff based on European and national legislation. 
Odbor CVMP je ugotovil, da so ukrepi za zmanjšanje površinskega odtoka že uveljavljeni na podlagi evropske in nacionalne zakonodaje.
Altrenogest is a synthetic steroidal hormone, an orally active progestogen. 
Altrenogest je sintetični steroidni hormon, peroralno aktiven progestogen.
Strength Pharmaceutical form 
Farmacevt-ska oblika
Animal species 
Žival-ska vrsta
The results from STEP 4 ranged from 16 pg/l (R1) to 219 pg/l (R3). 
Rezultati 4. koraka so znašali od 16 pg/l (R1) do 219 pg/l (R3).
The shift in sex ratio towards males clearly underlines the androgenic potential of the substance. 
Zaradi premika deleža po spolu k samcem je jasno poudarjen androgeni potencial snovi.
A survey of the national legislation in relation to Directive 91/676/EEC revealed that countries with a minimum distance of 1 and 2 m from the water body represent almost two-thirds of the total pig production in Europe. 
Pregled nacionalne zakonodaje v povezavi z Direktivo 91/676/EGS je pokazal, da države z najmanj metrsko in dvometrsko oddaljenostjo od vodnega telesa predstavljajo skoraj dve tretjini celotne prašičereje v Evropi.